Sciwind Biosciences rallies $70m Series C
Sciwind Biosciences Co, a developer of new therapies to treat metabolic disease, has secured $70 million in Series C financing.
Sciwind Biosciences Co, a developer of new therapies to treat metabolic disease, has secured $70 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination